Critical Care and Resuscitation最新文献

Objective: Frusemide is a common diuretic administered to critically ill children intravenously, by either continuous infusion (CI) or intermittent bolus (IB). We aim to describe the characteristics of children who receive intravenous frusemide, patterns of use, and incidence of acute kidney injury (AKI), and to investigate factors associated with commencing CI.

Design: Retrospective observational study.

Setting: Paediatric intensive care unit (PICU), the Royal Children's Hospital Melbourne.

Participants: Children who received intravenous frusemide during PICU admission lasting ≥24 h between 2017 and 2022.

Main outcome measures: The primary outcome was the daily dose of frusemide. Secondary outcomes included timing of therapy from PICU admission, fluid balance at frusemide initiation, additional diuretic therapy, and the incidence of AKI at admission and frusemide initiation. Children who received CI were compared with those who received IB only using multivariable logistic regression analyses.

Results: Nine thousand three ninety-four children were admitted during the study period. A total of 1387 children (15 %) received intravenous frusemide, including 220 children (16 %) by CI. The CI group were younger (132 vs 202 days, p = 0.01), had higher PIM-3 scores (2.2 vs 1.5, p-value <0.001), more congenital heart disease (CHD) (72.3 % vs 60.6 %, p <0.01), and higher incidence and severity of AKI at frusemide initiation than the IB group (65.7 % vs 40.1 %, p-value <0.001). CI were commenced later than IB (46 vs 19 h into admission, p <0.001) and at higher doses (4.3 vs 1.5 mg/kg/day, p-value <0.001). In multivariable analyses, CHD (aOR 1.67, 95 % CI 1.16-2.40, p <0.01) was associated with CI.

Conclusion: Frusemide infusions are administered more commonly to children with CHD, later in PICU admission, and at higher daily doses compared to IB. Children who receive CI have a higher incidence and severity of AKI at initiation.

Objective: To describe the incidence of bleeding and thrombotic complications in VA-ECMO according to anticoagulation strategy.

Design: This systematic review and meta-analysis included randomised controlled trials (RCTs) and observational studies reporting bleeding and thrombotic complications in VA-ECMO. The incidence of primary outcomes according to anticoagulation drug and monitoring test was described.

Data sources: CENTRAL, MEDLINE, Embase and CINAHL (2010-January 2024).

Review methods: Data was extracted using Covidence. A meta-analysis of proportions was performed using STATA MP v18.1 metaprop.

Results: We included 159 studies with 21,942 patients. No studies were at low risk of bias. The incidence of major bleeding or thrombotic events was similar among heparin-, bivalirudin- and anticoagulation-free cohorts. The pooled incidence of major bleeding and thrombotic complications were 40% (95%CI 36-44, I² = 97.12) and 17% (95%CI 14-19, I ²  = 92.60%), respectively. The most common bleeding site was thoracic. The most common ischaemic complication was limb ischaemia. The incidences of major bleeding or thrombotic events, intracranial haemorrhage and ischaemic stroke were similar among all monitoring tests. Mechanical unloading was associated with a high incidence of major bleeding events (60%, 95%CI 43-77, I² = 93.32), and ischaemic strokes (13%, 95%CI 7-19, I² = 81.80).

Conclusions: Available literature assessing the association between anticoagulation strategies in VA-ECMO, and bleeding and thrombosis is of limited quality. We identified a substantially higher incidence of major bleeding events than a previous meta-analysis. Limited numbers of patients anticoagulated with alternatives to heparin were reported. Patients with additional mechanical LV unloading represent a cohort at particular risk of bleeding and thrombotic complications.

Objective: To assess current evidence regarding guanfacine use in hospitalized patients with delirium.

Introduction: Delirium is a common and important complication of critical illness. Central alpha-2 agonists are often used for symptomatic management. Guanfacine is an enteral central alpha-2 agonist approved for the treatment of attention deficit hyperactivity disorders. However, its use for delirium treatment has not been systematically assessed.

Inclusion criteria: All studies of guanfacine to treat patients with delirium during hospitalization. We excluded reviews, letters, commentaries, correspondence, conference abstracts, expert opinions or editorials.

Methods: We performed a systematic search of the literature using: MEDLINE (Ovid), Embase (Ovid), CENTRAL and SCOPUS (Elsevier) from inception until 29 February, 2024. Two independent reviewers assessed the identified citations and abstracts. Data on study and patient characteristics, as well as efficacy and safety outcomes, were extracted. Efficacy was defined by guanfacine's ability to relieve delirium and improve clinical outcomes, including intensive care unit (ICU) length of stay (LOS), hospital LOS, and mortality. Safety was assessed for hemodynamic stability or other reported side effects.

Results: We screened 908 articles and included two case reports, one case series, two retrospective descriptive cohorts, and one retrospective analytic cohort. Guanfacine therapy was associated with delirium attenuation and a reduction in the use of sedative agents. Median dosage was 1.5 mg daily, with a median time to delirium improvement of 3 days. However, guanfacine therapy was not associated with decreased ICU or hospital LOS. The most frequently reported adverse events were mild hypotension and bradycardia.

Conclusion: There is limited data on the efficacy of guanfacine for the treatment of delirium. However, given its pharmacologic properties and its available safety data, controlled investigations may be justified.

Objectives: The objective of this study was to describe current use, clinical practice, and outcomes of continuous renal replacement therapy (CRRT) in children in the intensive care unit (ICU) in Australia and New Zealand.

Design: retrospective, binational registry-based cohort study and electronic survey of clinical practice.

Setting: ICUs that contribute to the Australian and New Zealand Paediatric Intensive Care Registry and a survey conducted in November 2021 including ICUs accredited for paediatric intensive care training that provide CRRT for children were part of this study.

Participants: Patients aged <18 years who received renal replacement therapy (RRT) in the ICU were included. Analysis of Australian and New Zealand Paediatric Intensive Care Registry data encompassed admissions from 1 January 2016 to 31 December 2020.

Interventions: None.

Main outcome measures: .

Results: 1378 of 58,736 (2.4%) ICU admissions received RRT (CRRT or peritoneal dialysis [PD]), of which 592 (1.0%) received CRRT. Patients receiving CRRT were older and had a median age of 43 months (interquartile range: 7-130 months) compared to 0.3 months (interquartile range: 0.1-2.6 months) for PD. CRRT was used more commonly in all patient groups (523/626, 84%), except those with congenital heart disease (CHD). The number of admissions receiving CRRT varied between units from 1 to 160 admissions for the 5-year period. Overall ICU mortality for CRRT was 30% (175/592). ICU mortality was the highest in neonates ([51/108] 47%) and in those with CHD ([40/69] 58%). ICU mortality for CRRT decreased over the 5-year study period (35%-22%, p = 0.025). The survey showed consistency in CRRT equipment used between units, but there were differences in choice of dialytic modality and anticoagulation regimen.

Conclusion: CRRT is used less frequently than PD in smaller children and in those with CHD. In all other cohorts, it is the predominant mode of RRT. ICU mortality rates were higher for CRRT than for PD, with a large variation in mortality rates across age and diagnostic groups. The CRRT mortality in ICU decreased over the 5 years of the study.

Objective: To describe the epidemiology and clinical features of pressure injury (PI) development in adult patients supported with extracorporeal membrane oxygenation (ECMO).

Design: Retrospective, observational, cohort study from January 2018 to May 2023.

Setting: A single-centre high-volume ECMO specialist intensive care unit (ICU).

Participants: All adults (aged 18 y or more) admitted to ICU for more than 24 h.

Main outcome measures: Any PI developing more than 24 h after ICU admission.

Results: Five-hundred ICU patients were supported with ECMO during the study period. Excluding those <18 years of age and with an ICU length of stay of <24 h, 466 patients were included in the analysis. One-hundred-thirty-five (29.0%) patients acquired at least one PI during their ICU stay, with PI occurring in 80 patients (17.2%) whilst supported on ECMO. The PI incidence rate was 1.7 per 100 ECMO patient-days (confidence interval: 1.3-2.0). Patients with a PI were mechanically ventilated for longer, received more renal replacement therapy, manifested more delirium, and stayed longer in the ICU and hospital. Conversely, crude ICU and in-hospital mortality was lower in the PI group. A longer ECMO run time and a higher proportion of veno-venous ECMO was also noted in those with a PI. Factors independently associated with the acquisition of a PI were male gender, oral dietary intake, renal replacement therapy, and prolonged mechanical ventilation. The majority of the PIs acquired during ECMO were stage-two and were most commonly located on the neck and head (n = 25/96 PIs, 26.0%) and sacral region (n = 31/96 PIs, 32.3%). Only three PIs were in relation to the ECMO cannula, circuit, or dressing.

Conclusion: A significant proportion of patients develop PIs while receiving ECMO. Vigilance on the prevention of medical device related PI is required. Gender, renal replacement therapy, oral diet, and length of mechanical ventilation were independent predictors for PI development in this population.

Objective: To describe the use of and outcomes from awake prone positioning (APP) in nonintubated patients with COVID-19 in Australian intensive care units (ICUs) in comparison to those who did not receive APP, and to explore the temporal relationship between publication of APP research and changes in clinical practice.

Design: Multicentre, observational cohort study.

Setting: Seventy-eight Australian ICUs participating in SPRINT-SARI Australia.

Participants: Adult patients with confirmed COVID-19 admitted to ICU from 27 February 2020 until 30 June 2022.

Main outcomes measures: Proportion of patients receiving APP, rates of invasive ventilation, hospital length of stay (LOS), in-hospital mortality.

Results: 4711 patients were included in the analysis, of whom 28.6% (1347/4711) underwent APP. Use of APP rapidly increased during the Delta wave and then subsequently declined. Over this period, there were a total of 30 publications on APP. APP patients received a median of 2 (IQR 1-4) days prone positioning, were less unwell (median APACHE-II 13.0 vs. 15.0, p < 0.001), and were less likely to require invasive ventilation (27.9% vs. 34.9%, p < 0.001). Overall, there was no difference in hospital LOS (median 14 vs. 13 days, P = 0.420) or in-hospital mortality (HR 0.95, 0.8-1.11) in those that did and did not receive APP. However, in patients requiring invasive ventilation after their first day in the ICU, not receiving APP was associated with earlier time to intubation (median 1 vs. 3 days, p < 0.001) and lower adjusted in-hospital mortality (HR 0.70, CI 0.54-0.90).

Conclusions: APP was rapidly adopted into practice within Australian ICUs during the COVID-19 pandemic at the same time as a growing number of publications on the topic. A lower frequency of invasive ventilation was noted with APP overall, but in those who eventually required this intervention, APP was associated with greater risk-adjusted in-hospital mortality.

Objective: Knowledge of intensive care unit (ICU) acquired hypernatremia (ICU-AH) has been hampered by the absence of granular data and confounded by variable definitions and inclusion criteria.

Design: Multicentre retrospective cohort study.

Setting: Twelve ICUs in Queensland (QLD), Australia.

Participants: Adult patients admitted to ICU from 2015 to 2021. Only the first ICU admission was considered, and we categorised patients into mild (146-150 mmol·L^-1), moderate (151-155 mmol·L^-1) and severe (>155 mmol·L^-1) ICU-acquired hypernatremia.

Main outcome measure: We aimed to study the prevalence of ICU-AH, patient characteristics, trajectory, risk factors, and outcomes.

Results: Data from 55,255 ICU admissions were included in the analysis, of which 4146 (7.5 %) patients had ICU-AH. These were subcategorised into mild (n = 2,670, 4.8 %), moderate (n = 1,073, 1.9 %) and severe (n = 403, 0.73 %) forms. Median time to diagnosis was 4 (2-6) d after ICU admission, while median time to peak serum sodium level was 5 (3-8) d. The median maximum sodium level across the cohort was 149 (147-152) mmol·L^-1. The sodium correction rate was 1 mmol·L^-1 per day, taking a median of 3 d (1-5) for sodium levels to return below 145 mmol·L^-1. APACHE III score, invasive ventilation, fever, and diuretic use on the day before hypernatremia were independent risk factors for moderate or severe ICU-AH. After adjusting for confounders, all levels of hypernatremia were independently associated with an increased risk of 30-d in-hospital mortality.

Conclusions: In a large multicentric study of critically ill patients, ICU-acquired hypernatremia occurred in one in eight admissions after a median of four days in the ICU and was preceded by identifiable and modifiable risk factors. If severe, its correction was slow, and normalisation was delayed. After adjusting for other factors, all levels of hypernatremia were an independent risk factor for 30-d in-hospital mortality.

Objective: Extracorporeal membrane oxygenation (ECMO) is a high-risk procedure with significant morbidity and mortality and there is an uncertain volume-outcome relationship, especially regarding long-term functional outcomes. The aim of this study was to examine the association between ECMO centre volume and long-term death and disability outcomes.

Design setting and participants: This is a registry-embedded observational cohort study. Patients were included if they were enrolled in the binational ECMO registry (EXCEL). The exclusion criteria included patients on ECMO for heart/lung transplants. Data included demographics, clinical information on their first ECMO run, and six-month outcomes obtained by telephone interview. The primary outcome was death or new disability at six months. A multivariable analysis was conducted using hospitals' annual ECMO volume. High-volume centres were defined as having >30 ECMO cases annually, and analyses were run on ECMO subgroups of veno-venous (VV), veno-arterial (VA), and extracorporeal cardiopulmonary resuscitation (ECPR).

Results: Of 1232 patients, 663 patients were cared for on ECMO at high-volume centres and 569 patients at low-volume centres. There was no difference in six-month death or new disability between high- and low-volume ECMO centres in VV-ECMO [OR: 1.09 (0.65-1.83), p = 0.744], VA-ECMO [OR: 1.10 (0.66-1.84), p = 0.708], and ECPR-ECMO [OR: 1.38 (0.37-5.08), p = 0.629]. This finding was persistent in all sensitivity analyses, including exclusion of patients who were transferred between high- and low-volume centres.

Conclusion: There was no difference in death or disability at six months between high- and low-volume centres in Australia and New Zealand, possibly due to the current model of coordinated care that includes patient transfers and training between high- and low-volume ECMO centres in our region.

Objective: The optimal timing of vasopressin initiation as an adjunctive vasopressor remains unclear. We aimed to study the association between the timing of vasopressin commencement, pre-specified physiological parameters, and hospital mortality.

Design: We conducted a multicentre, retrospective, observational study.

Setting: Twelve ICUs in Queensland, Australia between January 2015 and December 2021.

Participants: Adult patients with septic shock who received vasopressin as an adjunctive vasopressor within 72 hours of ICU admission.

Main outcome: Hospital mortality.

Results: Overall, 2747 patients fulfilled the inclusion criteria. Of these, 1850 (67%) started vasopressin within six hours of vasopressor therapy start, while 897 (33%) started vasopressin between six hours and 72 hours. APACHE III score, peak lactate, and creatinine were higher in the early start group. Early vasopressin start was independently associated with decreased hospital mortality (aOR = 0.69, 95% CI = 0.57-0.83). Vasopressin infusion start was also associated with an immediate decrease in the noradrenaline-equivalent dose regardless of timing. There was a statistically significant favourable breakpoint at vasopressin start for the course of arterial pH, lactate, heart rate and crystalloid infusion rate (p<0.001).

Conclusions: In patients with septic shock, early adjunctive vasopressin initiation was independently associated with lower hospital mortality. Vasopressin starting at any time was also associated with reduced tachycardia, acidosis, and hyperlactatemia.